180 related articles for article (PubMed ID: 25425335)
1. GATA-binding protein 3, gross cystic disease fluid protein-15 and mammaglobin have distinct prognostic implications in different invasive breast carcinoma subgroups.
Ni YB; Tsang JY; Chan SK; Tse GM
Histopathology; 2015 Jul; 67(1):96-105. PubMed ID: 25425335
[TBL] [Abstract][Full Text] [Related]
2. Immunohistochemical evaluation of GATA-3 expression in ER-negative breast carcinomas.
Liu H; Shi J; Prichard JW; Gong Y; Lin F
Am J Clin Pathol; 2014 May; 141(5):648-55. PubMed ID: 24713735
[TBL] [Abstract][Full Text] [Related]
3. Young investigator challenge: The utility of GATA3 immunohistochemistry in the evaluation of metastatic breast carcinomas in malignant effusions.
Lew M; Pang JC; Jing X; Fields KL; Roh MH
Cancer Cytopathol; 2015 Oct; 123(10):576-81. PubMed ID: 26465236
[TBL] [Abstract][Full Text] [Related]
4. GATA-3 is superior to GCDFP-15 and mammaglobin to identify primary and metastatic breast cancer.
Ni YB; Tsang JYS; Shao MM; Chan SK; Cheung SY; Tong J; To KF; Tse GM
Breast Cancer Res Treat; 2018 May; 169(1):25-32. PubMed ID: 29340880
[TBL] [Abstract][Full Text] [Related]
5. Utility of mammaglobin and gross cystic disease fluid protein-15 (GCDFP-15) in confirming a breast origin for recurrent tumors.
Chia SY; Thike AA; Cheok PY; Tan PH
Breast; 2010 Oct; 19(5):355-9. PubMed ID: 20347310
[TBL] [Abstract][Full Text] [Related]
6. Expression of mammaglobin and gross cystic disease fluid protein-15 in breast carcinomas.
Luo MH; Huang YH; Ni YB; Tsang JY; Chan SK; Shao MM; Tse GM
Hum Pathol; 2013 Jul; 44(7):1241-50. PubMed ID: 23332923
[TBL] [Abstract][Full Text] [Related]
7. GATA3 expression in clinically useful groups of breast carcinoma: a comparison with GCDFP15 and mammaglobin for identifying paired primary and metastatic tumors.
Yang Y; Lu S; Zeng W; Xie S; Xiao S
Ann Diagn Pathol; 2017 Feb; 26():1-5. PubMed ID: 28038704
[TBL] [Abstract][Full Text] [Related]
8. Co-expression and prognostic value of gross cystic disease fluid protein 15 and mammaglobin in primary breast cancer.
Fritzsche FR; Thomas A; Winzer KJ; Beyer B; Dankof A; Bellach J; Dahl E; Dietel M; Kristiansen G
Histol Histopathol; 2007 Nov; 22(11):1221-30. PubMed ID: 17647195
[TBL] [Abstract][Full Text] [Related]
9. GATA3 expression in morphologic subtypes of breast carcinoma: a comparison with gross cystic disease fluid protein 15 and mammaglobin.
Wendroth SM; Mentrikoski MJ; Wick MR
Ann Diagn Pathol; 2015 Feb; 19(1):6-9. PubMed ID: 25544392
[TBL] [Abstract][Full Text] [Related]
10. Utility of different immunostains for diagnosis of metastatic breast carcinomas in both surgical and cytological specimens.
Hou Y; Shen R; Chaudhary S; Tonkovich D; Li Z
Ann Diagn Pathol; 2017 Oct; 30():21-27. PubMed ID: 28965624
[TBL] [Abstract][Full Text] [Related]
11. Can GATA3 Immunocytochemistry be Utilized as a Reliable Diagnostic Marker for Metastatic Breast Carcinoma in Cytological Materials? A Comparative Study with Mammaglobin and GCDFP-15 Expression.
Hafez NH; Shaaban HM
Turk Patoloji Derg; 2018; 34(2):143-149. PubMed ID: 29235613
[TBL] [Abstract][Full Text] [Related]
12. Relationship between molecular subtype of invasive breast carcinoma and expression of gross cystic disease fluid protein 15 and mammaglobin.
Lewis GH; Subhawong AP; Nassar H; Vang R; Illei PB; Park BH; Argani P
Am J Clin Pathol; 2011 Apr; 135(4):587-91. PubMed ID: 21411781
[TBL] [Abstract][Full Text] [Related]
13. GATA-binding protein 3 enhances the utility of gross cystic disease fluid protein-15 and mammaglobin A in triple-negative breast cancer by immunohistochemistry.
Huo L; Gong Y; Guo M; Gilcrease MZ; Wu Y; Zhang H; Zhang J; Resetkova E; Hunt KK; Deavers MT
Histopathology; 2015 Aug; 67(2):245-54. PubMed ID: 25564996
[TBL] [Abstract][Full Text] [Related]
14. Utility of GATA3 immunohistochemistry for diagnosis of metastatic breast carcinoma in cytology specimens.
Braxton DR; Cohen C; Siddiqui MT
Diagn Cytopathol; 2015 Apr; 43(4):271-7. PubMed ID: 25088841
[TBL] [Abstract][Full Text] [Related]
15. GATA3: a promising marker for metastatic breast carcinoma in serous effusion specimens.
Shield PW; Papadimos DJ; Walsh MD
Cancer Cytopathol; 2014 Apr; 122(4):307-12. PubMed ID: 24421220
[TBL] [Abstract][Full Text] [Related]
16. Comparative study of monoclonal antibody B72.3 and gross cystic disease fluid protein-15 as markers of apocrine carcinoma of the breast.
Honma N; Takubo K; Arai T; Younes M; Kasumi F; Akiyama F; Sakamoto G
APMIS; 2006 Oct; 114(10):712-9. PubMed ID: 17004974
[TBL] [Abstract][Full Text] [Related]
17. GATA3 expression and its relationship with clinicopathological parameters in invasive breast carcinomas.
Cakir A; Isik Gonul I; Ekinci O; Cetin B; Benekli M; Uluoglu O
Pathol Res Pract; 2017 Mar; 213(3):227-234. PubMed ID: 28215639
[TBL] [Abstract][Full Text] [Related]
18. Expression of GCDFP-15 and AR decreases in larger or node-positive apocrine carcinomas of the breast.
Honma N; Takubo K; Akiyama F; Sawabe M; Arai T; Younes M; Kasumi F; Sakamoto G
Histopathology; 2005 Aug; 47(2):195-201. PubMed ID: 16045781
[TBL] [Abstract][Full Text] [Related]
19. Heat shock protein 27 and gross cystic disease fluid protein 15 play critical roles in molecular apocrine breast cancer.
Liu X; Feng C; Liu J; Zhao L; Liu J; Zhang W; Liu N; Niu Y
Tumour Biol; 2016 Jun; 37(6):8027-36. PubMed ID: 26711786
[TBL] [Abstract][Full Text] [Related]
20. Impact of GATA-3 and FOXA1 expression in patients with hormone receptor-positive/HER2-negative breast cancer.
Hisamatsu Y; Tokunaga E; Yamashita N; Akiyoshi S; Okada S; Nakashima Y; Taketani K; Aishima S; Oda Y; Morita M; Maehara Y
Breast Cancer; 2015 Sep; 22(5):520-8. PubMed ID: 24415069
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
